Relay Therapeutics, Inc. President and CEO Sanjiv Patel filed a Form 4 on November 20, 2026, disclosing the sale of 48,202 shares of common stock on November 19, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: Sanjiv Patel disposed of 48,202 shares of Relay Therapeutics common stock on November 19, 2026.
  • Weighted average price: The transaction was reported at a weighted average sale price of $16.13 per share, with individual trades ranging from $15.89 to $16.72.
  • 10b5-1 plan: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Patel on October 30, 2025.
  • Direct holdings after transaction: Following the sale, Patel directly owns 423,099 shares of common stock.
  • Indirect holdings: Patel is also associated with 199,548 shares held by The Patel Family Irrevocable Trust of 2019 and 687,355 shares held by The SSP Irrevocable Trust of 2020, though he disclaims beneficial ownership of both.

Patel 10b5-1 Sale Details and Beneficial Ownership at Relay Therapeutics

According to the filing, Sanjiv Patel, who serves as President and CEO and is also a Director of Relay Therapeutics, Inc. (NASDAQ:RLAY), sold 48,202 shares of common stock on November 19, 2026. The filing indicates the transaction was coded "S" (a sale) and was carried out under a Rule 10b5-1 trading plan that Patel adopted on October 30, 2025. The form notes that the transaction was "effected pursuant to a contract, instruction or written plan for the purchase or sale of equity securities."

The filing reports that the sale was executed in multiple trades at prices ranging from $15.89 to $16.72 per share, with the weighted average price recorded as $16.13. The filing states that Patel "undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote." Following the transaction, Patel directly holds 423,099 shares of Relay Therapeutics common stock.

In addition to his direct holdings, the filing discloses two blocks of shares held indirectly: 199,548 shares through The Patel Family Irrevocable Trust of 2019 and 687,355 shares through The SSP Irrevocable Trust of 2020. The filing states that both trusts are managed by an independent trustee and that Patel "disclaims beneficial ownership of these securities," adding that "the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose." No derivative securities transactions were reported in this filing.

What Was Disclosed

Sanjiv Patel, President and CEO of Relay Therapeutics, reported a sale of 48,202 shares of common stock on November 19, 2026, at a weighted average price of $16.13, under a pre-established Rule 10b5-1 plan, leaving him with 423,099 shares held directly.